Advanced Blockchain AG

WKN: A0M93V
ISIN: DE000A0M93V6
Land: Deutschland

Nachricht vom 04.03.2021 | 22:53

Advanced Blockchain AG: Capital increase fully placed

Advanced Blockchain AG / Key word(s): Cryptocurrency / Blockchain/Capital Increase
Advanced Blockchain AG: Capital increase fully placed

04-March-2021 / 22:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Frankfurt am Main, March 4th, 2021 - Advanced Blockchain AG (WKN: A0M93V, ISIN: DE000A0M93V6; Stock exchange: Düsseldorf [primary market]) announced today's capital increase from EUR 3,150,000.00 to up to EUR 3,381,000.00 by issuing up to 231,000 new, no-par value bearer shares against cash contributions, partially utilizing the existing authorized capital and excluding shareholders' subscription rights.

The total of 231,000 new shares were placed exclusively with qualified investors by way of a private placement at a placement price of EUR 16.65 per share. The gross issue volume was around EUR 3,846,150.00 million.
The transaction was accompanied by mwb fairtrade Wertpapierhandelsbank AG.

04-March-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	Advanced Blockchain AG
	Chausseestraße 86
	10115 Berlin
	Germany
Phone:	030403669510
Fax:	030403669511
E-mail:	info@advancedblockchain.com
Internet:	www.advancedblockchain.com
ISIN:	DE000A0M93V6
WKN:	A0M93V
Listed:	Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	1173344


End of Announcement	DGAP News Service

Kurschart

Kursdetails anzeigen

Interaktiv

DGAP-Watchlist

zur Registrierung

Übersicht Indizes

weitere Indizes

Weitere News

weitere News anzeigen

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Zur Studie